BR112016024419A8 - Vacina profilática contra a síndrome da queda de postura (eds) - Google Patents

Vacina profilática contra a síndrome da queda de postura (eds)

Info

Publication number
BR112016024419A8
BR112016024419A8 BR112016024419A BR112016024419A BR112016024419A8 BR 112016024419 A8 BR112016024419 A8 BR 112016024419A8 BR 112016024419 A BR112016024419 A BR 112016024419A BR 112016024419 A BR112016024419 A BR 112016024419A BR 112016024419 A8 BR112016024419 A8 BR 112016024419A8
Authority
BR
Brazil
Prior art keywords
eds
vaccine against
drop syndrome
against posture
prophylactic vaccine
Prior art date
Application number
BR112016024419A
Other languages
English (en)
Other versions
BR112016024419B1 (pt
BR112016024419A2 (pt
Inventor
Yamazaki Kenichi
Andoh Kiyohiko
Sakamoto Ryuichi
Suenaga Kiyotaka
Arakawa Takeshi
Uefuji Hirotaka
Harakuni Tetsuya
Miyata Takeshi
Original Assignee
The Chemo Sero Therapeutic Res Institute
Jectas Innovators Company Ltd
Meiji Animal Health Co Ltd
Km Biologics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Chemo Sero Therapeutic Res Institute, Jectas Innovators Company Ltd, Meiji Animal Health Co Ltd, Km Biologics Co Ltd filed Critical The Chemo Sero Therapeutic Res Institute
Publication of BR112016024419A2 publication Critical patent/BR112016024419A2/pt
Publication of BR112016024419A8 publication Critical patent/BR112016024419A8/pt
Publication of BR112016024419B1 publication Critical patent/BR112016024419B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10111—Atadenovirus, e.g. ovine adenovirus D
    • C12N2710/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10111—Atadenovirus, e.g. ovine adenovirus D
    • C12N2710/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/075—Adenoviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

VACINA PROFILÁTICA CONTRA A SÍNDROME DA QUEDA DE POSTURA (EDS). A presente invenção se destina a fornecer uma vacina contra a síndrome da queda de postura (EDS) que é capaz de prevenir, de forma eficaz, a EDS e pode ser fornecida de forma estável. Para resolver esse problema, é fornecida uma vacina de EDS que compreende, como um ingrediente ativo, uma proteína fundida na qual um polipeptídeo com uma unidade de formação enrolada em espiral está ligado à região globular na proteína fibrosa do vírus de EDS (EDSV).
BR112016024419-2A 2014-04-21 2015-03-16 Proteína fundida, seu multímero, vacina contra a síndrome da queda de postura (eds), seu uso e kits BR112016024419B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014-087620 2014-04-21
JP2014087620 2014-04-21
PCT/JP2015/057657 WO2015163037A1 (ja) 2014-04-21 2015-03-16 産卵低下症候群（ｅｄｓ）予防ワクチン

Publications (3)

Publication Number Publication Date
BR112016024419A2 BR112016024419A2 (pt) 2017-11-14
BR112016024419A8 true BR112016024419A8 (pt) 2023-01-31
BR112016024419B1 BR112016024419B1 (pt) 2023-09-26

Family

ID=54332208

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016024419-2A BR112016024419B1 (pt) 2014-04-21 2015-03-16 Proteína fundida, seu multímero, vacina contra a síndrome da queda de postura (eds), seu uso e kits

Country Status (8)

Country Link
US (1) US10253072B2 (pt)
EP (1) EP3135764A4 (pt)
JP (1) JP6620386B2 (pt)
CN (1) CN106232813B (pt)
BR (1) BR112016024419B1 (pt)
MX (1) MX370079B (pt)
RU (1) RU2720978C2 (pt)
WO (1) WO2015163037A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10253072B2 (en) * 2014-04-21 2019-04-09 Km Biologics Co., Ltd. Prophylactic vaccine against egg drop syndrome (EDS)
WO2017104796A1 (ja) * 2015-12-16 2017-06-22 国立大学法人 岡山大学 人工ｒｎａ制限酵素
CN108567976A (zh) * 2017-03-10 2018-09-25 成都贝爱特生物科技有限公司 鸡新城疫、减蛋综合征二联基因工程亚单位疫苗的制备方法和应用
CN108653724B (zh) * 2017-04-01 2020-11-27 普莱柯生物工程股份有限公司 一种用于预防禽减蛋综合征的疫苗组合物、及其制备方法和应用
CN110092840B (zh) * 2019-05-15 2023-01-17 青岛明勤生物科技有限公司 一种鸡传染性喉气管炎、减蛋综合征二联多表位疫苗
CN112679585B (zh) * 2019-10-17 2023-06-30 普莱柯生物工程股份有限公司 包含禽减蛋综合征病毒基因工程亚单位疫苗的疫苗组合物及其制备方法和应用
CN112708637B (zh) * 2019-10-25 2022-06-24 苏州世诺生物技术有限公司 禽减蛋综合症病毒新型基因工程疫苗、其制备方法与应用
CN110981968B (zh) * 2019-12-17 2022-05-27 天康制药(苏州)有限公司 含有狂犬病病毒g蛋白的融合蛋白及其制备方法、应用和疫苗
CN114573708B (zh) * 2020-11-30 2024-05-17 普莱柯生物工程股份有限公司 副鸡禽杆菌ha融合蛋白及其三聚体、制备的疫苗组合物、制备方法和应用
CN115960179A (zh) * 2022-10-19 2023-04-14 扬州优邦生物药品有限公司 血清4型禽腺病毒elisa抗体检测试剂盒

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003209648A1 (en) * 2003-03-04 2004-09-28 Abic Ltd. Subunits of the adenovirus fiber protein and uses thereof as vaccines
US20050137156A1 (en) * 2003-08-09 2005-06-23 Johnston Stephen A. Methods and compositions for generating an immune response
EP2397547A4 (en) * 2009-02-10 2012-09-05 Univ Ryukyus ACTIVE TRANSPORT, AS WELL AS AUXILIARY AND VACCINATE THEREOF
MX368398B (es) * 2012-10-22 2019-10-01 Jectas Innovators Company Ltd Vacuna para prevenir la enfermedad de edema porcino.
US10253072B2 (en) * 2014-04-21 2019-04-09 Km Biologics Co., Ltd. Prophylactic vaccine against egg drop syndrome (EDS)

Also Published As

Publication number Publication date
WO2015163037A1 (ja) 2015-10-29
RU2016145061A3 (pt) 2019-02-15
JP6620386B2 (ja) 2019-12-18
JPWO2015163037A1 (ja) 2017-04-13
EP3135764A1 (en) 2017-03-01
RU2016145061A (ru) 2018-05-21
MX2016013819A (es) 2017-03-09
RU2720978C2 (ru) 2020-05-15
EP3135764A4 (en) 2017-12-27
BR112016024419B1 (pt) 2023-09-26
BR112016024419A2 (pt) 2017-11-14
MX370079B (es) 2019-11-29
CN106232813A (zh) 2016-12-14
US10253072B2 (en) 2019-04-09
US20170044217A1 (en) 2017-02-16
CN106232813B (zh) 2021-01-22

Similar Documents

Publication Publication Date Title
BR112016024419A8 (pt) Vacina profilática contra a síndrome da queda de postura (eds)
CL2016002934A1 (es) Anticuerpos humanos frente a la proteína de anclaje del coronavirus causante del síndrome respiratorio de oriente medio
EA201791117A1 (ru) Частичные агонисты инсулинового рецептора
CO2017002333A2 (es) Un artículo desechable que incluye por lo menos una región elástica unida
TWD178108S (zh) 瓶之部分
BR112017005381A2 (pt) composições que compreendem células recombinantes de bacillus e um inseticida.
BR112016024494A2 (pt) análogos de peptídeo com sonda(s) de aminoácidos ramificados
MX2015016755A (es) Reagrupamiento del virus de influenza.
BR102015017380A2 (pt) dispositivo para a reticulação do tecido do olho, e, composição farmacêutica
BR112018003178A2 (pt) absorvente feminino com braçadeiras de barreira
BR112017013103A2 (pt) porca segmentada
BR112017005504A2 (pt) composições que compreendem células recombinantes de bacillus e um inseticida.
TWD175009S (zh) 自動靜電槍
BR112015021880A2 (pt) rearranjo de vírus influenza b
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
BR112016019389A8 (pt) Vacina, e, peptídeo
BR112018077210A2 (pt) vírus de enterite de pato e usos do mesmo
BR112015012483A2 (pt) capô de turbomáquina com a capacidade de recobrir um cone de soprador
BR112018007055A2 (pt) dispositivo de processamento de informações.
BR112018000126A2 (pt) fibra de pbi fosforada
BR112017010459A2 (pt) dispositivo para transporte da luz
TWD174079S (zh) 平板狀配線構件連接用轉接器
ITUA20163068A1 (it) Busto ortopedico iperestensore con snodo sferico
BR112016028192A2 (pt) gerritdina g. schoonus-gerritsma

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: JECTAS INNOVATORS COMPANY LIMITED (JP) , THE CHEMO

B25A Requested transfer of rights approved

Owner name: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE (JP)

B25G Requested change of headquarter approved

Owner name: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE (JP)

B25A Requested transfer of rights approved

Owner name: KM BIOLOGICS CO., LTD. (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 7.4 NA RPI NO 2544 DE 08/10/2019 POR TER SIDO INDEVIDA.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: MEIJI ANIMAL HEALTH CO., LTD. (JP)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/03/2015, OBSERVADAS AS CONDICOES LEGAIS